MEI PharmaMEIP
MEIP
About: MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.
Employees: 28
0
Funds holding %
of 7,323 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
2,700% more call options, than puts
Call options by funds: $28K | Put options by funds: $1K
0.53% less ownership
Funds ownership: 40.61% [Q4 2024] → 40.08% (-0.53%) [Q1 2025]
3% less funds holding
Funds holding: 32 [Q4 2024] → 31 (-1) [Q1 2025]
12% less capital invested
Capital invested by funds: $6.65M [Q4 2024] → $5.85M (-$807K) [Q1 2025]
33% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 9
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
Research analyst outlook
We haven’t received any recent analyst ratings for MEIP.
Financial journalist opinion
Based on 4 articles about MEIP published over the past 30 days
Neutral
TheNewswire
5 days ago
BTC digital asset field continues to exert its strength, HASHJ launches Bitcoin cloud mining platform with "capital + technology" dual-driven mode
[UK, July 24, 2025] - BTC As the blockchain industry enters a new round of market cycle, the multi-currency linkage effect gradually emerges, and the price of BTC today starts to rise at 118875.30. According to foreign media reports such as Investing, with the continuous inflow of US spot ETF funds, the acceleration of technology implementation by the Ethereum Layer 2 Industry Alliance, and the launch of the network upgrade of Dogecoin (DOGE), Bitcoin's "safe-haven attribute" as a market value anchor has once again attracted capital favor, and its network computing power and BTC mining income have increased significantly. Another major positive news this week also boosted BTC confidence: MEI Pharmaceuticals (NASDAQ: MEIP) announced that Litecoin (LTC) will be included in the corporate treasury portfolio and completed the allocation of digital assets worth $100 million, which has aroused the capital market's deep attention to the reserve allocation model of encrypted assets. This behavior not only verifies the trust of mainstream institutions in encrypted assets, but also indirectly drives the prices of major currencies including Bitcoin to rise simultaneously. Hashj made timely adjustments to the market and provided new members with a maximum registration reward of $118 for BTC mining experience.
Neutral
Business Wire
1 week ago
MEI Pharma Announces Closing of $100,000,000 Private Placement to Initiate Litecoin Treasury Strategy, Becoming First and Only Publicly Traded LTC Holder on a National Exchange
SAN DIEGO--(BUSINESS WIRE)--MEI Pharma Announces Closing of $100,000,000 Private Placement to Initiate Litecoin Treasury Strategy.
Positive
Benzinga
1 week ago
Why Is MEI Pharma Stock Soaring On Friday?
MEI Pharma, Inc. MEIP stock is trading higher on Friday, with a session volume of 35.64 million compared to the average volume of 29.8K, as per data from Benzinga Pro.
Neutral
Business Wire
1 week ago
MEI Pharma Announces $100,000,000 Private Placement to Initiate Litecoin Treasury Strategy, Becoming First and Only Publicly Traded LTC Holder on a National Exchange
SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP) (the “Company” or “MEI”) today announced that it has entered into securities purchase agreements for a private investment in public equity (PIPE) for the purchase and sale of 29,239,767 shares of common stock (or pre-funded warrants in lieu thereof) at a price of $3.42 per share, for expected aggregate gross proceeds of approximately $100 million, before deducting placement agent fees and other estimated offering expenses. In connectio.
Neutral
Business Wire
2 months ago
MEI Pharma Reports Third Quarter Fiscal Year 2025 Cash Position
SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP) (the “Company”) today reported results for its third quarter ended March 31, 2025. As previously announced in July 2024, the Company is continuing its review and evaluation of potential strategic alternatives. As part of this assessment, the Company is considering options such as out-licensing opportunities for existing programs and merger and acquisition opportunities, with the goal of maximizing the value of its assets for its stockh.
Neutral
Business Wire
5 months ago
MEI Pharma Reports Second Quarter Fiscal Year 2025 Cash Position
SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP) (the “Company”) today reported results for its quarter ended December 31, 2024. As previously announced in July 2024, the Company is continuing its review and evaluation of potential strategic alternatives. As part of this assessment, the Company continues to consider options such as out-licensing opportunities for existing programs and merger and acquisition opportunities, with the goal of maximizing the value of its assets for its st.
Neutral
Business Wire
8 months ago
MEI Pharma Reports First Quarter Fiscal Year 2025 Cash Position
SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP) (the “Company”) today reported results for its quarter ended September 30, 2024. As previously announced in July 2024, the Company is continuing its review and evaluation of potential strategic alternatives. In the review, the Company continues to consider options such as out-licensing opportunities for existing programs and merger and acquisition opportunities, with the goal of maximizing the value of its assets for its stockholders.
Neutral
Business Wire
10 months ago
MEI Pharma Reports Fiscal Year End 2024 Cash Position
SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP) (the “Company”) today reported results for its fiscal year ended June 30, 2024. Previously on July 22, 2024, the Company announced the commencement of an evaluation of strategic alternatives with the goal of maximizing the value of its assets for its stockholders. Subsequent to that date, the Company announced the engagement of Oppenheimer & Co., Inc. to serve as the Company's exclusive financial adviser to assist in the review and.
Neutral
Business Wire
11 months ago
MEI Pharma Engages Oppenheimer & Co. Inc. to Assist in Evaluating Strategic Alternatives
SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP) (the “Company”) today announced that it has engaged Oppenheimer & Co. Inc. to serve as the Company's exclusive financial advisor to assist in its previously announced process to review and evaluate strategic alternatives. The Company remains focused on maximizing the value of its assets for its stockholders. There can be no assurance the exploration of strategic alternatives will result in any agreements or transactions, or, if com.
Neutral
Business Wire
1 year ago
MEI Pharma to Consider Strategic Alternatives
SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP) (the “Company”) today announced that its Board of Directors has determined unanimously to begin evaluation of the Company's strategic alternatives, including potential transactions as well as an orderly wind down of the Company, if appropriate, in order to maximize the value of its assets for its stockholders. The Company intends to evaluate and engage a financial advisor to assist in this process. In order to best preserve the Company.
Charts implemented using Lightweight Charts™